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Cytochrome P450 enzymes (CYP) are important catalyzing proteins involved in
the biotransformation of endogenous and xenobiotic compounds. However, their
expression and/or activity can be altered by exposure to contaminants such
as mycotoxins. In vitro incubations in porcine hepatic microsomes revealed a
potent inhibition of the midazolam (CYP3A) biotransformation by T-2 toxin (T-2)
(Ki = 27.0 ± 3.97 µM) and zearalenone (ZEA) (Ki = 1.1 ± 0.22 µM). Consequently,
the in vivo impact of 2 weeks exposure to T-2 (1,000 µg/kg feed) or ZEA (500 µg/kg
feed) on the pharmacokinetics (PK) of midazolam (MDZ) as a CYP3A probe drug was
investigated in pigs, and was compared to a control group receiving no mycotoxins.
MDZ was chosen as this drug undergoes substantial first-pass metabolism in humans
with equal contribution of the intestine and liver. Each pig received a single intravenous
(0.036 mg/kg BW) and oral (0.15 mg/kg BW) dose of midazolam (MDZ). For the IV bolus
no differences were observed in PK between control and mycotoxins exposed groups.
However, oral plasma concentration-time profiles showed quantitative differences
in absolute oral bioavailability F [p-value (ANOVA) = 0.022], AUC_0-inf (µg∗h/L) [p-
value (ANOVA) = 0.023], Ke (1/h) [p-value (ANOVA) = 0.004], and Ka (1/h) [p-value
(ANOVA) = 0.031]. Although only differences in Ke estimates after oral administration
reached significance in the post hoc analysis due to inequality of the variances. We
hypothesize that the observed trends after ZEA and T-2 exposure are related to the
cytotoxic effect of T-2, resulting in an increased absorption rate constant Ka. For
ZEA, an inhibition of the CYP3A enzymes is suggested based on the in vitro inhibition
potential and increase in oral bioavailability. Further research is required to confirm the
current hypothesis.
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INTRODUCTION
Cytochrome P450 enzymes (CYP) are a superfamily of drug
metabolizing enzymes facilitating drug elimination (Nebert and
Dalton, 2006). It is well known that xenobiotics can alter the
CYP metabolism by inducing or inhibiting these enzymes either
directly or through regulating mechanisms (Tanaka, 1998). Such
alterations can lead to clinical relevant pharmacokinetic drug-
drug and drug-food interactions. Examples are co-administration
of the strong CYP3A inhibitor ketoconazole with maraviroc, of
itraconazole with erythromycin, and of the intestinal CYP3A
inhibiting compounds in grapefruit-juice with felodipine (Bailey
et al., 1998; Tanaka, 1998; Abel et al., 2008).
Changes in drug disposition can also occur when drugs and
food-contaminants are co-ingested. However, such interactions
are far less investigated then the previous mentioned drug-
drug and drug-food interactions. One of the most abundant
food and feed contaminants are mycotoxins, contaminating up
to 72% of the feed (Streit et al., 2013; Lee and Ryu, 2017).
With deoxynivalenol (DON), zearalenone (ZEA), fumonisin B1
(FB1), and T-2 toxin (T-2) as the most important Fusarium
mycotoxins in terms of prevalence and/or toxicity (Streit et al.,
2013; Escrivá et al., 2015).
Deoxynivalenol and T-2 toxin exert their toxicity through
inhibition of the protein synthesis and the activation of mitogen
activated protein kinases, leading to inflammation, apoptosis,
and altered immune responses (Pestka, 2007; Escrivá et al.,
2015). The molecular targets of ZEA are estrogen receptors,
causing alteration in the reproductive tract (Fink-Gremmels and
Malekinejad, 2007; Streit et al., 2013; Escrivá et al., 2015). Finally,
FB1, is a very potent ceramide synthase inhibitor, resulting in the
accumulation of sphinganine and sphingosine ultimately causing
apoptosis, and growth inhibition (Escrivá et al., 2015).
Although the mechanism of action of DON, ZEA, T-2,
and FB1 are well studied, information about their impact
on CYP is scant. Furthermore, the influence on the in vivo
disposition of substrate drugs, after mycotoxin exposure, is
even less subject to investigation. Up to now, the available
studies focus primarily on the impact of mycotoxins on the
regulation of these enzymes (Guerre et al., 2000; Spotti et al.,
2000; Meissonnier et al., 2008; Ayed-Boussema et al., 2010; Duca
and Mabondzo, 2010; Goossens et al., 2013; Osselaere et al., 2013;
Antonissen et al., 2017).
In rats, FB1 can induce CYP2E1 activity while reducing
CYP2C11 and CYP1A2 activity (Spotti et al., 2000), whereas
in broiler chickens FB1 can induce CYP1A4 expression
(Antonissen et al., 2017). In the latter reference also the influence
of DON on the CYP1A4, CYP1A5, and CYP3A37 mRNA
expression was investigated, but the results were not significant
(Antonissen et al., 2017). In mice, however, DON induced
CYP1A and CYP3A related activities when the dose was
0.071 mg/kg body weight (BW) and higher. Exposure to
0.25 mg/kg BW of T-2 on the other hand, reduced CYP1A1/2,
CYP2A1, and CYP2B4 activity in rabbits (Guerre et al., 2000).
In broiler chickens, contamination of 752 µg T-2/kg feed, was
able to reduce the mRNA expression of CYP1A4/5 and CYP3A37,
in contrast to an increased activity in CYP3A related reactions
(Osselaere et al., 2013). In the pig, feed contaminated with 903
to 2,102 µg/kg T-2 significantly reduced CYP3A and CYP1A
activities (Meissonnier et al., 2008; Goossens et al., 2013). ZEA
has shown to be able to induce CYP3A4, CYP2B6, and CYP1A1
in addition to the activation of CYP regulation proteins like
the pregnane X receptor (PXR), constitutive androstane receptor
(CAR), and arylhydrocarbon receptor (AhR) in primary human
hepatocytes (Ayed-Boussema et al., 2010). These observations
were also made in PXR transfected HepG2 cells where ZEA
induced the CYP3A4 expression (Ding et al., 2006). In addition,
ZEA and T-2 have been proven to be, in part, metabolized by CYP
enzymes in microsomes and by recombinant enzymes, which
raises a risk for interactions with drugs (Bravin et al., 2009;
Pfeiffer et al., 2009; Ge et al., 2010; Lin et al., 2015). However,
the direct impact of these toxins on the biotransformation
capabilities of CYP enzymes and in vivo disposition of victim
substrate drugs is unknown.
The different species used in previous experiments like mouse,
rat, and rabbits are often not a representative model to estimate
the potential risk for humans (Bogaards et al., 2000; Zuber et al.,
2002; Cao et al., 2006; Turpeinen et al., 2007). Pigs however,
have been demonstrated to have a good resemblance in CYP
biotransformation to human drug CYP metabolism (Millecam
et al., 2018; Schelstraete et al., unpublished). Furthermore,
they have a similar anatomy and physiology of the gastro-
intestinal tract, liver, and circulatory system (Bode et al.,
2010; Swindle et al., 2012). These features are vital for a
representative animal model as in the in vivo setting, the
intestine, and liver are the two main sites of metabolism.
Thus, when investigating food contaminant effects on in vivo
drug metabolism, substrates undergoing intestinal, and hepatic
biotransformation are preferred substrate drugs. An example of
such substrate is MDZ. It is almost completely absorbed and
undergoes first-pass metabolism with equal contribution of the
intestine and liver (Thummel et al., 1996).
Therefore the goals of the present study were twofold. The
first goal was to investigate the direct effects of ZEA, T-2,
DON, and FB1 on 6 major porcine CYP enzymes. These direct
effects, in addition to an altered regulation of these enzymes,
can lead to changes in the disposition of victim substrate drugs,
eventually resulting in treatment failure, toxic responses, or
altered withdrawal times. Where inhibition is revealed, the type
of inhibition mechanism is elucidated. Second, these results are
used as guidance to select a relevant mycotoxin-CYP3A substrate
interaction and evaluate the impact on the in vivo disposition of
MDZ as CYP3A model substrate drug in pigs during a pilot study.
MATERIALS AND METHODS
Chemicals and Reagents
Zearalenone, T-2, DON, and FB1 were obtained from Fermentek
(Jerusalem, Israel). Phenacetin (PH), paracetamol (PAR),
tolbutamide (TB), 7-hydroxy-coumarin (OH-CM), dextrorphan-
D3, coumarin (CM), chlorzoxazone (CZ), and trifluoroacetic
acid (TFA) were delivered by Sigma-Aldrich (St. Louis, MO,
United States). MDZ, 1-hydroxy-midazolam (OH-MDZ),
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OH-MDZ-D4, 4-hydroxy-tolbutamide (OH-TB), 6-hydroxy-
chlorzoxazone (OH-CZ) were purchased at LGC standards
(Molsheim, France). Dextromethorphan (DXM), dextrorphan
tartrate (DEX), 7-hydroxycoumarin-D5, paracetamol-D4,
and OH-TB-D9 were from Toronto Research Chemicals
(North York, ON, Canada). OH-CZ-13C6 was obtained from
Alsachim (Illkirch Graffenstaden, France). NADPH was
obtained from OYC Europe (Rotterdam, Netherlands). All other
chemicals were of HPLC grade. Potassium chloride, potassium
dihydrogenphosphate, potassium hydrogenphosphate, formic
acid, and glycerol were bought at VWR (Leuven, Belgium).
Stock solutions of each substrate and toxin were prepared
in MeOH (MDZ, 3.26 mg/mL; CM, 0.13 mg/mL; DXM,
6.67 mg/mL; PH, 16.14 mg/mL; T-2, DON, ZEA, and FB1
1 mg/mL) or ACN (TB, 48.66 mg/mL; CZ, 15.26 mg/mL; SFZ,
0.32 mg/mL; DDC, 9.01 mg/mL) and stored at −20◦C. Fresh
working solutions were prepared by adding an appropriate
amount of stock solution to HPLC-quality water. The stop
reagent consisted of 55% ACN, 42% HPLC water, and 3% formic
acid with internal standards (final concentrations: 40, 100, 100,
200, 200, and 40 ng/mL for OH-MDZ-D4, OH-CZ-13C6, OH-
TB-D9, OH-CM-D5, PAR-D4, and DXT-D3, respectively). All
stock solutions were stored at−20◦C.
In vitro Experiments
Animal Tissues and Preparation of the Microsomes
Sixteen livers were obtained from conventional pigs (hybrid
sow× Piétrain boars, 12 weeks of age, 8 boars and 8 sows) reused
from a previous trial (approval EC2015_213) in the context of
animal reduction. After euthanasia with pentobarbital, with prior
sedation of a Zoletil R© (tiletamine-zolazepam, 20 mg/mL) and Xyl-
M R© (xylazine, 2%) mixture 1/2 (m/m), livers were excised and
rinsed twice in phosphate buffered saline and immediately frozen
in liquid nitrogen. Microsomes were prepared as previously
described (Wilson et al., 2003). In brief, liver samples were thawed
on ice, submerged in 0.25 M phosphate buffer containing 1.15%
potassium chloride (pH 7.25). Subsequently, 4 grams of liver
were minced and homogenized in 16 mL of a 0.25 M phosphate
buffer by the use of a Potter-Elvehjem homogenizer. Samples
were centrifuged for 25 min at 10,000 g and 4◦C. After decanting,
the supernatant was centrifuged for 80 min at 100,000 g and 4◦C.
Next, samples were washed with 4∗3 mL 0.25 M phosphate buffer
and centrifuged for a second time for 80 min at 100,000 g and
4◦C. The obtained pellet was suspended in 1.5 mL/g liver 0.25 M
phosphate buffer containing 1.15% potassium chloride and 30%
glycerol, snap frozen, and stored at −80◦C. All handlings were
performed on ice.
Microsomal proteins were determined according to
the method of Bradford (Bradford, 1976), following the
manufactures instructions.
Incubations of Microsomal CYP With and
Without Mycotoxins
Each incubation was performed at 37◦C in a thermoshaker TS
100 (Biosan, Riga, Latvia), and was repeated three times. Each
incubation medium consisted of 50 µL of a 0.2 M phosphate
buffer, 50 µL of microsomes diluted to 1.25 mg proteins/mL (for
TB incubations), or 0.5 mg proteins/mL (for other incubations),
50 µL of an aqueous 1.15% potassium chloride solution, 50 µL
of a substrate and/or mycotoxin working solution of different
concentrations, and 50 µL of a 25 mM NADPH solution. Before
adding NADPH, the mixture was pre-incubated for 5 min. The
organic solvent content was kept below 1%. Incubation time
was dependent on the substrate investigated and was 5 min for
PH (CYP1A), CM (CYP2A), DXM (CYP2D), CZ (CYP2E), and
MDZ (CYP3A). For TB (CYP2C) incubation time was 10 min.
After the specified incubation times, 125 µL of stop reagent was
added. Samples were further processed as described in the sample
preparation and chromatographic analysis section.
To be able to identify relevant interactions, an orientation
experiment was set up. In this experiment substrates were
incubated with and without the addition of mycotoxins. Each
mycotoxin was added to obtain a final concentration of 10 µM in
the incubation mixture. To account for possible time dependent
effect, the experiment was performed with and without a prior
incubation of 5 min of the mycotoxins. Based on these results,
mycotoxins showing inhibition (as defined by <80% residual
CYP enzyme activity), as well as absolute and relative differences
between the two experiments, were used as guidance for selecting
mycotoxin-substrate pairs for investigation of the inhibition type.
The 80% cut-off results from a simulation (n = 10,000) in which
the addition of an inhibitor has no effect and given the precision
of the analytical procedure is ≤10%. The limit was calculated
such that the probability of finding a percentage lower than the
threshold due to chance was ≤10%.
The selected mycotoxin-substrate pairs were incubated at
varying concentrations of substrate and inhibitor as depicted
in Supplementary Table 2. Incubations were identical as
described above.
Sample Preparation and LC-MS/MS Analysis of
Substrate Drug Metabolites in Incubated
Microsomal Media
After adding the stop reagent, 125 µL of TFA was added and
samples were subsequently centrifuged at 16,200 g for 10 min.
The supernatant was decanted in 15 mL conical tubes, containing
1 mL of a 0.2 M phosphate buffer. Next, 7 mL of ethyl acetate
were added and the samples were extracted during 15 min on an
overhead shaker (IKA R© TRAYSTER, Staufen, Germany) at room
temperature. The two phases were separated by centrifugation
at 1,000 g for 5 min. The organic phase was transferred in
a glass vial and evaporated under a gentle nitrogen stream at
40 ± 5◦C. After evaporation of the organic phase, 0.2 mL of a
50/50 methanol/HPLC water mixture were added and an aliquot
of 10 µL was injected into the HPLC equipment. The samples
were analyzed according to a previously reported and validated
HPLC-MS/MS method (Schelstraete et al., 2018).
In vivo Experiments
In vivo Animal Trial With ZEA and T-2
All procedures used in the animal trial were in accordance to
the ethical standards of the ethical committee of the Faculties
of Veterinary Medicine and Bioscience Engineering of Ghent
University (approval EC2017_91). Twenty-four conventional
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pigs (hybrid sow × Piétrain boars, ILVO, Melle, Belgium),
7 weeks of age, were randomly divided in 3 groups of 8 pigs
(4 males and 4 females). For a 2 week period, each group was
fed with either control feed, T-2 contaminated (1,000 µg/kg),
or ZEA (500 µg/kg) contaminated feed. The contaminated feed
was prepared by adding the toxins (analytical grade) to the
compound feed. The pigs receiving mycotoxin contaminated
feed were administered 0.5 kg of contaminated feed/pig in the
morning and 0.5 kg of control feed/pig in the afternoon. This
corresponds to a mean intake of 500 and 250 µg/kg feed of T-2
and ZEA, respectively. This correlates with a mean intake of feed
contaminated with levels equal to the maximal guidance levels
according to 2006/576/EG and 2013/165/EU. For the control
group, 0.5 kg of control feed/pig was given at each occasion.
After the 2 weeks feeding period, MDZ was administered to
each pig as a single intravenous bolus (0.036 mg/kg BW) and
blood samples (±1 mL) were collected in Vacutest R© heparine
tubes, with a 21G needle (Novolab, Geraardsbergen, Belgium)
at 0, 0.083, 0.166, 0.333, 0.500, 0.666, 1, 1.5, 2, 3, 4, 6, 8, and
10 h post-administration (p.a.). Blood samples were taken by
restraining the pigs and direct venipuncture of the vena jugularis
externa. After a 48 h wash out period, the pigs were administered
an oral bolus (0.15 mg/kg BW) and blood samples were collected
at the same time points. The doses were selected in order to have
minimal sedative effect. In line with this, the IV dose was about
1/4 compared to the PO dose. Blood samples were centrifuged for
10 min at 4,000 g and the supernatant plasma was transferred to
a vial and stored at −20◦C until analysis. At the end of the trial,
pigs were euthanized as described above.
Determination of Midazolam and
1-Hydroxy-Midazolam in Plasma
The quantification of MDZ and OH-MDZ was performed on
a Waters R© Alliance 2690 separation module and autosampler
(Waters, Milford, CT, United States), coupled to a Waters
Quattro Ultima R© triple quadrupole mass spectrometer
(Micromass Waters, Manchester, United Kingdom). Separation
was performed on a Zorbax Eclipse Plus C18 column
(100 mm × 3.0 mm i.d., 3.5 µm d.p.). The mobile phases
consisted of 0.1% formic acid in HPLC water (mobile phase
A) and 0.1% formic acid in methanol (mobile phase B). The
following gradient was used (A/B%): 0–4 min, 85:15 to 40:60;
4–4.1 min, 40:60 to 10:90; 4.1–5 min, 10:90; 5–5.1 min, 10:90
to 85:15; 5.1–10min, 85:15. The mass spectrometer features
were set as previously described in Schelstraete et al. (2018).
The method was in-house validated for precision, accuracy,
linearity, limit of quantification (LOQ), limit of detection (LOD)
specificity and carry-over following guidelines of the European
Commission (2002/657/EC) and international guidelines. Limits
of quantification for MDZ and OH-MDZ were 0.1 ng/mL.
Data and Statistical Analysis
Results of the incubation experiments were analyzed using
Sigmaplot R© version 13 (Systat Software, San Jose, CA,
United States). To unravel the type of inhibition, eight different
equations were fitted against the data (Supplementary Table 1).
The different types were competitive, partial competitive, non-
competitive, partial non-competitive, uncompetitive, partial
uncompetitive, mixed, and partial mixed inhibition. Model
selection was based on inspection of the residual plots, Akaike
information criterion, passing homogeneity tests for residuals
and significance of the parameter estimates.
The pharmacokinetic (PK) data were processed using
Phoenix R© version 8.1 (Certara, Princeton, NJ, United States).
A non-compartmental analysis (NCA) was performed to
calculate the area under the plasma concentration-time curve
(AUC_0-inf), clearance (Cl), volume of distribution (Vd), and
the elimination rate constant (ke) after IV dosing. AUC_0-inf,
Cl, Vd, Cmax (maximal plasma concentration), Tmax (time to
Cmax), Ke, absorption rate constant (Ka), and F (absolute oral
bioavailability) were calculated after PO dosing. Oral Cl and Vd
were corrected for the bioavailability F.
Statistical analysis of the estimated parameters was performed
in SPSS version 25 (IBM, Armonk, NY, United States). The
parameters were log-transformed and ANOVA was carried out
to detect mean differences amongst the groups. A post hoc Tukey
test was used if the variances were equal, as evaluated by the
Levene’s test. If the assumption of equal variances was violated,
a Dunnett’s T3 test was performed. The significant level was
set at α = 0.05.
RESULTS
Orientation Experiment
The results of the orientation experiments are presented in
Table 1. Deoxynivalenol inhibited none of the reactions more
than 20% without pre-incubation of the mycotoxins, therefore
DON was not considered for further investigation. In contrast,
ZEA could strongly inhibit the CYP2C (TB-hydroxylation) and
CYP3A (MDZ-hydroxylation) activities and slightly the CYP2D
(DXM-demethylation) activity. Consequently they were selected
TABLE 1 | Results from the orientation experiment.
TB
(CYP2C)
CZ
(CYP2E)
CM
(CYP2A)
PH
(CYP1A)
MDZ
(CYP3A)
DXM
(CYP2D)
Without mycotoxin pre-incubation
DON 111 92.8 87.2 95.6 102 98.0
ZEA 9.40 39.1 96.1 97.0 16.6 73.8
T-2 62.3 79.5 99.1 96.7 115 99.1
FB1 110 69.8 19.3 70.9 118 91.5
With mycotoxin pre-incubation
DON 68.8 57.6 42.5 64.9 66.0 68.4
ZEA 5.50 27.9 73.4 62.7 7.50 66.3
T-2 46.3 65.4 72.5 78.2 34.4 94.2
FB1 77.5 59.2 12.6 49.5 78.8 75.5
Results are expressed as mean residual activity compared to control incubation
without mycotoxin (%, n = 3). Mycotoxins were added 5 min before the substrate if
a pre-incubation step was included. DON, deoxynivalenol; ZEA, zearalenone; T-2,
T-2 toxin; FB1, fumonisin B1; TB, tolbutamide; CZ, chlorzoxazone; CM, coumarin;
PH, phenacetin; MDZ, midazolam; DXM, dextromethorphan. The full dataset can
be found in Supplementary Data Sheet 1.
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for further investigation. ZEA could also markedly reduce CYP2E
(CZ-hydroxylation) related activities, however, recent data show
that this reaction can also be catalyzed by CYP3A, CYP2C, and
CYP2A enzymes (Schelstraete et al., unpublished). Because the
reduction of CZ-hydroxylation is paralleled by a reduction in
CYP3A and CYP2C activities upon incubation with ZEA and
by a reduction in CYP2A (CM-hydroxylation) activity upon
incubation with FB1, it was hypothesized that the CYP2E enzyme
was probably not inhibited by the investigated mycotoxins.
T-2 toxin could moderately inhibit the CYP2C
biotransformation without pre-incubation of the toxin. However,
after pre-incubating T-2 for 5 min, the CYP3A activity was
strongly reduced. The relative reduction in CYP3A activity
(compared to the incubation without mycotoxin pre-incubation)
was higher compared to the other investigated reactions.
Therefore, the interaction between T-2 and MDZ was studied
more profoundly after pre-incubation of the mycotoxin, while
for the interaction with TB no pre-incubation was included.
Fumonisin B1 reduced the CYP2E (CZ), CYP2A (CM),
and CYP1A (PH) enzyme activity by more than 20%. Given
that the inhibition of CM was very strong and the fact that
simultaneous experiments (Schelstraete et al., unpublished)
showed that porcine CYP2A19 also contributes to PH and CZ
biotransformation, the moderate inhibition of CZ and PH was
considered to arise from the inhibition of CYP2A19 and was
therefore not considered for further elaboration.
Evaluation of the Inhibition Type of the
Selected Mycotoxins
The results of the curve fitting analysis from incubations with
different concentrations of mycotoxins and probe substrate are
given in Table 2. In this table, the Vmax, and Km values
are the values corresponding to an inhibitor concentration
of zero. The functional relation between the parameters is
shown in Supplementary Table 1, where the equations can
be found. Noticeable is that ZEA and T-2 could fairly potent
inhibit the MDZ and TB biotransformation, as demonstrated
by relative low inhibitory constant (Ki) values. Additionally,
FB1 showed a high affinity toward CYP2A19 enzymes (CM-
hydroxylation) since the Ki value was low, although the
efficacy (17% inhibition at highest FB1-CM concentration) was
low compared to that of T-2 and ZEA toward CYP3A and
CYP2C enzymes (MDZ- and TB-hydroxylation, <30% residual
activity). As a consequence, ZEA, and T-2 were selected for
the assessment of their impact on the in vivo disposition
of MDZ in the pig.
In vivo Impact of ZEA and T-2 on the
Disposition of Midazolam
Mean plasma concentration-time profiles of MDZ after
both administrations are displayed in Figure 1. Parameter
estimates resulting from PK NCA after IV and PO dosing are
given in Table 3.
After IV administration of MDZ, a trend for the AUC (0-inf)
was apparent from the mean plasma concentration-time profile
of MDZ in the ZEA group. However, no statistical significant
differences in parameter estimates could be observed [lowest
p = 0.42 for AUC (0-inf)]. Of notice are the results for Cl, Vd,
and Ke amongst the three groups, with nearly identical estimates,
which suggest equal elimination characteristics. This is also
reflected in the profiles (Figure 1A), as the plasma concentration
of MDZ declines in parallel amongst all groups.
In contrast to the kinetic profiles after an IV dose, the
plasma concentration-time course of MDZ after oral dosing
were more divergent. Indeed, as Figure 1B shows, an increasing
trend in mean Cmax values were observed in the mycotoxin
treated groups (p = 0.238). In addition, the AUC (0-inf) for
MDZ in the ZEA group was about 2.5 times higher on average,
which was significant in the ANOVA analysis (p = 0.023), but
adjusting for the unequal variances (Levene’s test, p = 0.003),
the post hoc analysis was not significant (lowest p-value: ZEA-
T-2: p = 0.106; ZEA-Control: p = 0.263). Again, as with the IV
dosing, a remarkable similar result in Cl is observed amongst
the three groups. However, the average Vd estimate of the T-2
exposed group was somewhat lower, but not statistical significant
(p = 0.174). Considering this similar Cl and lower Vd, the
T-2 group showed a statistical significant higher Ke estimate
(p = 0.004), highlighting a potential different elimination half-life
in the T-2 group. Furthermore, the average Ka of the T-2 group
was about 2.5 times higher compared to the control group. The
result of the ANOVA was significant (p = 0.031), but also here the
adjustment for the uneaqual variances (Levene’s test, p = 0.012)
TABLE 2 | Results of the curve fitting analysis.
Interaction Inhibition type Vmax (pmol/mg protein/min) Km (µM) Ki (µM) α β Residual activity∗ (%)
ZEA-TB Partial competitive 160 (16.0) 1074(137.9) 0.54(0.043) 9.5 (1.05) NA 18.7 (0.35)
ZEA-MDZ Partial mixed 2155 (73.8) 12.3(1.10) 1.1(0.22) 3.8 (1.43) 0.26 (0.064) 27.0 (3.16)
ZEA-DXM Full non-competitive 1971 (39.7) 2.0(0.17) 55.4(5.77) NA NA 32.0 (1.27)
T-2-TB Full competitive 132 (17.9) 804(150.0) 14.8(1.45) NA NA 24.0 (1.38)
T-2-MDZ Full non-competitive 1899 (88.2) 11.3(1.32) 27.0(3.97) NA NA 83.5 (2.41)
FB1-CM Full mixed 359 (4.1) 0.91(0.051) 2.3(0.34) 14.0 (4.30) NA 22.8 (3.50)
Parameter estimates are expressed as mean value (standard deviation). For each interaction, 4 different mycotoxin concentrations were used in combination with 6
different substrate concentrations. Each incubation was performed in triplicate. ZEA, zearalenone; T-2, T-2 toxin; FB1, fumonisin B1; TB, tolbutamide; CM, coumarin;
MDZ, midazolam; DXM, dextromethorphan; Km, Michaelis-Menten constant; Ki, inhibitory constant; α, affinity constant modulator for enzyme-inhibitor complex; β,
catalytic constant of the enzyme-substrate-inhibitor complex; NA, not available. ∗Residual activity at the highest concentration of substrate and inhibitor. The full dataset
can be found in Supplementary Data Sheet 2.
Frontiers in Pharmacology | www.frontiersin.org 5 April 2019 | Volume 10 | Article 399
fphar-10-00399 April 14, 2019 Time: 11:9 # 6
Schelstraete et al. Impact of T-2 and ZEA on Midazolam Pharmacokinetics
FIGURE 1 | Mean (+SD) plasma concentration-time profiles for midazolam (MDZ) after administration of a single intravenous dose of 0.036 mg/kg BW (A) and oral
dose of 0.15 mg/kg BW (B). Control and T-2 group: n = 8, 4 boars and 4 sows, 9 weeks of age; ZEA group: n = 7, 4 boars and 3 sows, 9 weeks of age.
TABLE 3 | PK parameter estimates obtained by non-compartmental analysis after
IV dosing of midazolam (0.036 mg/kg BW) and PO dosing of midazolam
(0.15 mg/kg BW).
Administration
route
Parameter Control ZEA T-2
IV AUC (0-inf)
(µg∗h/L)
11.5(1.51) 18.0(12.44) 13.0(6.69)
Vd (L) 60.8(23.17) 63.4(35.02) 62.9(32.01)
Cl (L/h) 46.0(7.51) 45.5(22.75) 45.8(16.41)
Ke (1/h) 0.83(0.279) 0.69(0.176) 0.79(0.215)
MRT (h) 0.71(0.110) 0.92(0.472) 0.63(0.086)
PO AUC (0-inf)
(µg∗h/L)
18.4(7.51) 46.1(39.9) 13.6(4.62)
Vd (L) 128(40.4) 136(93.8) 76.2(43.25)
Cl (L/h) 46.0(7.51) 44.1(27.73) 45.8(16.41)
Ke (1/h) 0.390(0.137) 0.390(0.121) 0.68(0.227)
Ka (1/h) 0.426(0.289) 0.419(0.130) 1.19(0.904)
F 0.36(0.136) 0.69(0.429) 0.27(0.124)
Cmax (µg/L) 5.45(4.230) 12.0(10.19) 8.85(5.720)
Tmax (h) 1.15(0.490) 1.14(0.900) 1.13(1.270)
MRT (h) 3.58(0.884) 3.46(0.840) 2.24(1.352)
Results are presented as mean (standard deviation) (control and T-2 group: n = 8,
4 boars and 4 sows, 9 weeks of age; ZEA group: n = 7, 4 boars and 3 sows,
9 weeks of age). AUC (0-inf), area under the plasma concentration-time curve from
time = 0 min to infinity; Vd, volume of distribution; Cl, clearance; Ke, elimination
rate constant; Ka, absorption rate constant; F, bioavailability; Cmax, maximal
concentration; Tmax, time to maximal concentration; MRT, mean residence time.
The full dataset can be found in Supplementary Data Sheet 3.
rendered the post hoc analysis not significant (lowest p-value: T-
2-Control, p = 0.104). A change in Ka should result in a change
in Tmax values. However, this was not reflected in the average
Tmax for the T-2 group. The reason is that one pig showed
a Tmax of 4 h, while the other Tmax values ranged between
0.16 and 1.5 h. In the control group this range was between
0.67 and 2 h. Removing the observation from the analysis
resulted in a mean Tmax value of 0.714 ± 0.559 h. However,
the result was not significantly different amongst the groups
(p = 0.170). Lastly, the average F differed amongst the groups
(ANOVA, p = 0.022), nevertheless this results was marginally
non-significant (p = 0.093).
Besides MDZ, also OH-MDZ -the principal MDZ metabolite-
was measured and the plasma concentration-time profiles are
depicted in Figure 2. Mean AUC and Cmax values can be found
in Table 4. Although, by inspection of the plots in Figure 2,
elimination of OH-MDZ is rather similar due to the comparable
decline in plasma concentration after Cmax. The average AUC
and Cmax after IV bolus administration was smaller in the
control group, although not significant (p = 0.104). In contrast,
after PO administration, AUC values for the control and T-
2 group were nearly identical on average. The highest average
Cmax value for OH-MDZ was observed for the T-2 and ZEA
group, which aligns with the high Cmax values of the MDZ
concentration in these groups (Table 4).
DISCUSSION
The objectives of the current study were twofold. On the
one hand, the inhibitory potential and inhibition type of four
frequently occurring Fusarium mycotoxins, DON, ZEA, T-2, and
FB1 (Supplementary Figure 1), on porcine CYP enzymes were
investigated. On the other hand, the influence of ZEA and T-2 on
the disposition of MDZ in the pig was studied.
In the orientation experiments, DON could not inhibit
any of the investigated probe reactions for CYP1A, CYP2A,
CYP3A, CYP2C, CYP2D, and CYP2E. This observation aligns
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FIGURE 2 | Mean (+SD) plasma concentration-time profiles for 1-hydroxymidazolam after an intravenous dose of 0.036 mg/kg BW MDZ (A) and an oral dose
0.15 mg/kg BW of MDZ (B). Control and T-2 group: n = 8, 4 boars and 4 sows, 9 weeks of age; ZEA group: n = 7, 4 boars and 3 sows, 9 weeks of age.
TABLE 4 | AUC and Cmax values for OH-MDZ after IV and PO
administration of midazolam.
AUC_IV
(µg∗h/L)
Cmax_IV
(µg/L)
AUC_PO
(µg∗h/L)
Cmax_PO
(µg/L)
Control 0.46 ± 0.195 0.32 ± 0.115 2.28 ± 1.521 0.81 ± 0.587
ZEA 0.81 ± 0.557 0.48 ± 0.145 3.43 ± 1.991 1.24 ± 1.013
T-2 0.83 ± 0.642 0.41 ± 0.147 2.28 ± 0.665 1.73 ± 0.980
Values are represented as mean ± standard deviation (n = 8 for control and T-2
group, 4 boars and 4 sows, 9 weeks of age; n = 7 for ZEA group, 4 boars and 3
sows, 9 weeks of age).
with previous reports, stating that DON is not subject to
phase I metabolism (Côté et al., 1987; Maul et al., 2012).
In contrast, T-2 could moderately inhibit the CYP2C probe
reaction (TB-hydroxylation) without a pre-incubation, while
relative strong inhibition was seen for the CYP3A probe
reaction (MDZ-hydroxylation) after including a pre-incubation
step. Wang et al. (2011) suggested a role of porcine CYP2C
in the metabolism of T-2 (Wang et al., 2011). Furthermore,
various members of the porcine CYP3A family have been
demonstrated to convert T-2 and HT-2 toxin (HT-2) to its
3′-hydroxy metabolites (Ge et al., 2010; Wang et al., 2011;
Wu et al., 2011). The current results are in agreement
with these studies and indicate that porcine CYP2C and
CYP3A enzymes most likely play a key role in the phase I
metabolism of T-2. This is an important feature as it can
possibly lead to kinetic interactions between T-2 and substrates
of these enzymes.
The corresponding type of inhibition of T-2 toward TB-
hydroxylation and MDZ-hydroxylation was full-competitive
and full-non-competitive, respectively. The full-competitive
inhibition implies that T-2 can directly inhibit CYP2C enzymes
by binding to their active site, whereas the non-competitive
inhibition toward CYP3A enzymes, indicates that either T-2 or
a metabolite binds on an allosteric site or loss of functional
enzyme occurs during incubation due to irreversible binding
(Leskovac, 2004). Since the biotransformation of T-2 or HT-
2 by CYP3A enzymes does not change the intrinsic reactive
epoxide ring, it is unlikely that an irreversible complex is formed
(Wang et al., 2011; Wu et al., 2014). However, the pre-incubation
results in formation of metabolites of T-2 and HT-2 prior to
incubation with substrates. Consequently, these metabolites can
occupy allosteric sites, inducing conformational changes of the
enzyme, rendering it less active.
The main biotransformation route for ZEA is a reduction
to α-zearalenol (α-ZEL) and β-zearalenol (β-ZEL), catalyzed
by steroid dehydrogenases (Malekinejad et al., 2006; Devreese
et al., 2015). However, ZEA and its reduced metabolites
can also be oxidized by CYP enzymes (Bravin et al., 2009;
Pfeiffer et al., 2009). The CYP enzymes contributing to the
oxidative metabolism of ZEA, α-ZEL, and β-ZEL are mainly
the CYP1A, CYP2C, CYP3A subfamilies, next to the minor
CYP2D contribution in humans (Bravin et al., 2009; Pfeiffer
et al., 2009). Furthermore, in the rat the oxidations are also
catalyzed by CYP2C members (Bravin et al., 2009). In the current
study, ZEA could strongly inhibit the TB-hydroxylation (CYP2C)
and MDZ-hydroxylation (CYP3A) reactions, and weakly the
DXM-demethylation (CYP2D) reaction. Although, ZEA also
inhibited CZ-hydroxylation (CYP2E). Nevertheless, this was
considered to result from the inhibition of CYP3A and CYP2C
enzymes, which contribute to this reaction as previously reported
(Schelstraete et al., unpublished).
The strong, competitive-like inhibition of MDZ- and TB-
hydroxylation suggests that porcine CYP2C and CYP3A enzymes
contribute to the oxidation of ZEA and/or its metabolites.
In addition, the weaker, noncompetitive inhibition of DXM-
demethylation indicates a minor role of porcine CYP2D,
similar as in humans (Pfeiffer et al., 2009). Therefore, the
results of the inhibition pattern of ZEA and T-2 further
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support the appropriateness of the pig as an animal model in
compound safety testing.
Hitherto no phase I metabolism is known for FB1 (Cawood
et al., 1994). Although, it is known that the porcine gut microbiota
can hydrolyze FB1 and that rats excrete unspecified metabolites
in urine (Shephard et al., 1992; Fodor et al., 2008). In the
current investigation, FB1 could reduce the CM activity at the
concentrations tested in the orientation experiment. Coumarin
is solely metabolized by porcine CYP2A (Schelstraete et al.,
unpublished). Moreover, this enzyme is the most abundant CYP
enzyme in porcine liver microsomes and has a broader substrate
specificity compared to human CYP2A. Therefore, it might be
possible that porcine CYP2A is capable of hydrolyzing FB1 and
therefore affects CM-hydroxylation. However, further research is
required to strengthen this hypothesis.
From the results of the in vitro experiments, ZEA, and T-
2 were selected for the investigation of their effects on the
in vivo disposition of MDZ as a CYP3A probe. These toxins were
selected because T-2 had a time dependent effect and ZEA can
induce mRNA synthesis in human primary hepatocytes, mouse
and rat livers (Ding et al., 2006; Ayed-Boussema et al., 2010;
Duca and Mabondzo, 2010), hence, the effects can accumulate
over time. MDZ in turn has the ideal property of being almost
completely absorbed and further metabolized by both intestinal
and hepatic CYP3A (Thummel et al., 1996). Consequently it
allows to differentiate between the effects of the toxins on the
intestine and liver.
After IV administration of MDZ to the different test groups,
no differences in AUC (0-inf), Cl, Vd, and Ke were observed,
indicating the effects of T-2 and ZEA on the CYP3A activity in
the liver are limited. These observations are somewhat in contrast
to the results of Goossens et al. (2013) were a reduced OH-
MDZ formation was observed in hepatic microsomes prepared
from pigs exposed to 903 µg T-2/kg feed for 14 days (Goossens
et al., 2013). Possibly these discrepancies can be attributed to the
difference in exposure to T-2. In this study, pigs were exposed on
average to 500 µg of T-2/day vs. 903 µg/kg feed fed ad libitum
in the mentioned study. Furthermore, when T-2 is administered
orally to pigs, even at doses of 2.4 mg/kg BW, no parent toxin
could be detected in plasma nor liver (Beasley et al., 1986),
indicating that T-2 is unlikely to directly affect the metabolism
in the liver due to the high intestinal biotransformation (Beasley
et al., 1986; Wu et al., 2012). In addition, after intra-aortal
administration of 1.2 mg T-2 to pigs, a mean elimination half-life
of 13.8 min was observed, further supporting the hypothesis that
T-2 is not likely to directly affect the hepatic metabolism due to
high first-pass and/or short exposure time (Beasley et al., 1986).
In contrast to T-2, ZEA can induce mRNA synthesis and
CYP3A activity in human primary hepatocytes, mouse, and
rat hepatocytes (Ding et al., 2006; Ayed-Boussema et al., 2010;
Duca and Mabondzo, 2010). However, no increased elimination
of MDZ was observed in vivo in the current study. Again,
these differences can be attributed to a different exposure to
the toxin. In the in vitro settings, the concentrations ranged
from 0.03183 to 15.92 µg/mL (Ding et al., 2006; Ayed-Boussema
et al., 2010), whereas in the in vivo investigation, rats were
exposed to 25 mg/kg BW (Duca and Mabondzo, 2010), which
are high compared to a total daily intake of 250 µg ZEA in
the present study.
Compared to the IV profiles, PK profiles after PO
administration of MDZ were more divergent. Quantitative
differences in absolute oral bioavailability F[p-value
(ANOVA) = 0.022], AUC_0-inf (µg∗h/L) [p-value
(ANOVA) = 0.023], Ke (1/h) [p-value (ANOVA) = 0.004], and Ka
(1/h) [p-value (ANOVA) = 0.031] were observed, although only
the Ke showed a significant difference (p-value = 0.017) after
post hoc testing due to unequal variances observed amongst the
groups. This increased variability can originate form differences
in feed intake due to hierarchy within each pen, or differences
in response to mycotoxin exposure. Nevertheless, some relevant
trends could be noticed. Compared to the control group, pigs
receiving T-2 tend to have higher average Cmax, Ke, and Ka
values but a similar AUC (0-inf) estimate. The ZEA group on
the other hand, showed an increasing trend in Cmax, F, and
AUC (0-inf) values but with similar Ke and Ka estimates. Higher
average Cmax, Ka, and F values for MDZ in the toxin treated
groups indicate that MDZ is absorbed faster or less eliminated
before reaching the systemic circulation. As both the intestine
and the liver contribute to the first-pass metabolism of MDZ
(Thummel et al., 1996), and no differences in elimination were
found after IV administration, the observed differences most
likely originate from changes occurring in the intestine. From the
results presented in the current study and information available
in other reports, it ishypothesized that this is either due to altered
epithelial integrity or reduced biotransformation. However, a
larger scale study is required to confirm the current findings.
There is some evidence in literature which align with this
hypothesis of reduced epithelial integrity and to the observations
for the PK of MDZ in the T-2 group. Indeed, T-2 is strongly
cytotoxic and has the potential to interfere with the intestinal
epithelial cells (Goossens et al., 2012a,b). Concentrations as low
as 10 ng/mL (21.43 nM) of T-2 have been shown to significantly
affect the epithelial integrity of IPEC-J2 cells causing a threefold
increase in doxycycline and more than 50-fold increase in
paromomycin passage across IPEC-J2 cells (Goossens et al.,
2012a). With a mean intake of 500 µg T-2/day, concentrations
of more than 21.43 nM (10 ng/mL) in the intestinal lumen
are reasonable to assume. This increase in epithelial transfer
is reflected in the higher average Ka for MDZ in the T-2
group, which was significant different between groups (ANOVA,
p = 0.031; post hoc T-2-Control p = 0.104). As a consequence of
faster absorption, Cmax values are also elevated but the AUC (0-
inf) is unaffected, as the Ka has no influence on this parameter.
A similar observation was made for doxycycline when pigs were
exposed for 7 days to 100 µg T-2/kg feed (Goossens et al., 2012b).
Besides the Ka and Cmax, also the Ke estimate (p = 0.017)
increased. Closer inspection of the pharmacokinetic profiles of
the T-2 group vs. the ZEA and control group, reveal a double
absorption peak in the latter two groups. Due to the high
reactivity of T-2, it is likely that only the first part of the
small intestine is affected, leading to increased or even total
absorption over this initial part and consequently the absence of
a second absorption peak. This faster absorption and absence of a
second peak can explain the apparently higher-elimination in the
Frontiers in Pharmacology | www.frontiersin.org 8 April 2019 | Volume 10 | Article 399
fphar-10-00399 April 14, 2019 Time: 11:9 # 9
Schelstraete et al. Impact of T-2 and ZEA on Midazolam Pharmacokinetics
T-2 group. The latter hypothesis corresponds with the
observation that maximal OH-MDZ concentrations tend to be
higher in the T-2 treated group.
In contrast to T-2, ZEA is less cytotoxic for the intestinal
epithelial cells, only affecting IPEC-J2 cell viability at
concentrations of 40 µM (12.73 µg/mL) (Wan et al., 2013).
As the mean ZEA intake was only 250 µg/day, concentrations
of 40 µM in the intestinal lumen are unlikely. Consequently
the impairment of the intestinal barrier function is unlikely.
However, for the direct inhibition of ZEA toward CYP3A
enzymes, the Ki value is 1.1 µM. Assuming a combined water
content of about 720 mL in the stomach and small intestine
from pigs provided water ad libitum (Merchant et al., 2011),
concentrations of 1.1 µM ZEA can be reached. In addition, ZEA
is subject to entero-hepatic circulation, leading to prolonged
exposure of the enterocytes to ZEA and metabolites over the
length of the small intestine (Dänicke et al., 2005). Therefore it
can be hypothesized that the increasing trend of Cmax, AUC (0-
inf), and F in the ZEA group results from the intestinal CYP3A
inhibition. Although the in vitro experiments were based on
hepatic microsomes, we previously showed that the same CYP3A
isoenzymes are expressed in the intestine (Schelstraete et al.,
unpublished). An inhibition of intestinal CYP3A metabolism
does not influence Ka but it can have pronounced effects on F
-and consequently the AUC (0-inf)- because it depends on the
intestinal and hepatic first-pass. Furthermore the concentration
time course for the control and ZEA groups was similar, which
further supports the hypothesis of CYP3A inhibition by ZEA
(or metabolites) over the length of the small intestine. Finally,
the higher average Cmax for MDZ in the toxin treated groups
translates in a higher average Cmax in the OH-MDZ.
Determination of the CYP3A enzymes in the intestine
would have aided to confirm our hypothesis. However, the
variability in activity is large and expression is different along
the tract (Van Peer et al., 2014; Schelstraete et al., 2018).
In addition, these enzymes were previously quantified in the
intestinal microsomes (Schelstraete et al., unpublished). The
CYP enzymes detected belonged to the CYP3A and CYP2C
subfamily, with a total amount detected of 3.44 ± 2.42 pmol/mg
protein. This value is about 100-fold lower than in hepatic
microsomes. Furthermore, the detected amounts of intestinal
CYP enzymes were near the analytical limits, making it extremely
difficult to detect a treatment difference. Nevertheless, with
the fast increase in available mass spectrometry methods and
increasing sensitivity, this approach should be included in
future research.
In conclusion, ZEA and T-2 have a tendency to influence the
pharmacokinetics (PK) of MDZ, a typical CYP3A substrate, at
realistic levels of mycotoxin contamination, although the results
were only significant for Ke and marginally non-significant
for F, and Ka. However, a larger follow-up study should be
performed to confirm the current findings. The results of the
present study allow to calculate an appropriate sample size for
this future research. As DON and ZEA are frequently occurring
in food and feed, they can affect pharmacotherapy. Indeed,
alterations in biotransformation capacities can lead to an altered
exposure and have deleterious effects on therapeutic outcome
of substrate drugs. In addition these alterations can potentially
lead to toxic responses and longer than expected withdrawal
times for some therapeutics. Finally, as porcine and human
CYP3A closely resemble each other, co-ingestion of ZEA and T-
2 contaminated food with drugs can possibly affect human drug
disposition as well.
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